GSK Links With OncoMed, Galapagos To Boost Oncologic, Anti-Infective Pipelines
This article was originally published in The Pink Sheet Daily
Executive Summary
Deals present possible $1.4 billion for OncoMed, €245 million for Galapagos through GSK’s external drug discovery centers.
You may also be interested in...
Novel Cancer Therapies Aim To Destroy The Disease At Its Root: The Cancer Stem Cell
Micromet and Geron gave progress reports on their stem cell targeting therapies at the American Association for Cancer Research meeting.
Novel Cancer Therapies Aim To Destroy The Disease At Its Root: The Cancer Stem Cell
Micromet and Geron gave progress reports on their stem cell targeting therapies at the American Association for Cancer Research meeting.
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q4 2008
Highlights from the Q4 2008 review of pharmaceutical and biotechnology dealmaking: Financing dollar volume was only one-fourth that of Q3 with 57 deals bringing in over $1.09 billion, with no IPOs or FOPOs, but early-stage VC rounds accounting for 41% of this total. M&A dollars also were down: $7.6 billion in Q4--versus the $25.2 billion of the previous quarter--and contributing just 15% to the category's 2008 annual total. Alliances saw the most activity, boasting ten deals with pre-commercialization values greater than $100 million. Five of those were over $275 million, including Bristol-Myers Squibb Inc.'s $850 million tie up with Exelixis Inc., not only the fourth quarter's highest, but the second-largest alliance of the year.